A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors by unknown
POSTER PRESENTATION Open Access
A Phase I study of NLG919 for adult patients with
recurrent advanced solid tumors
Asha Nayak1, Zhonglin Hao1, Ramses Sadek1, Nicholas Vahanian2, W Jay Ramsey2, Eugene Kennedy2*,
Mario Mautino2, Charles Link2, Pamela Bourbo1, Robin Dobbins1, Kelly Adams1, Allison Diamond1, Lisa Marshall1,
David H Munn1, John Janik1, Samir N Khleif3
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Clinical Trial Registration Number: NCT02048709
Background
The enzyme Indoleamine 2,3-dioxygenase (IDO1) cata-
lyzes the cleavage of L-tryptophan, resulting in the pro-
duction of kynurenine. Tryptophan depletion and
kynurenine metabolites enhance the number and function
of Tregs (suppressive arm) and inhibit effector T cells (sti-
mulatory arm), regulating acquired local and peripheral
immune tolerance. In cancer, IDO can either be expressed
directly by the tumor cells themselves, or induced indir-
ectly in host antigen presenting cells by the tumor and its
expression has been associated with a worse clinical out-
come in a variety of cancers. Indoximod (1-methyl D-tryp-
tophan), the first IDO pathway inhibitor to enter human
clinical trials, is currently being tested in multiple Phase II
clinical trials. We are here to report preliminary Phase I
data with another promising IDO pathway inhibitor,
NLG919, a potent direct enzymatic inhibitor of IDO.
While Indoximod and NLG919 both target the same IDO
pathway, preclinical data clearly demonstrates that these
compounds have different mechanisms of action and are
synergistic. In preclinical models, NLG919 showed dose-
dependent activation and proliferation of effector T cells,
producing dramatic regression of large established tumors.
Additionally, NLG919 showed enhanced immune activa-
tion and tumor regression when combined with Indoxi-
mod in this system.
Methods
In this Phase I trial six dose levels of NLG919 are proposed
for evaluation: 50, 100, 200, 400, 600 and 800 mg orally
q12 h for 21 of 28 days in repeating cycles. Patients with
advanced solid tumors that have progressed following stan-
dard therapy are eligible unless prior Ipilimumab or other
CTLA4 targeted therapy has been administered. A single
patient was treated at the first dose level and patients have
been enrolled on subsequent dose levels with a standard 3
+ 3 escalation scheme. Pharmacokinetics are evaluated for
48 hours following the first dose with no intervening doses
at the initiation of the first cycle, and also at the end of the
treatment cycle, day 21.
To date, no dose limiting toxicities have been observed
and detailed updated study results will be presented. The
primary objectives of the study are to evaluate the safety
and toxicity of NLG919 in patients with advanced solid
tumors and to define the maximum tolerated dose and
recommended dose for Phase II studies. Secondary objec-
tives are to measure pharmacokinetics, pharmacodynamics
and evaluate any potential antitumor responses.
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